ArticleHuman vaccines & immunotherapeutics2025
Identifying HPV vaccination research priorities for the US.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To guide researchers and funders, we sought to identify top priorities for research on increasing HPV vaccine coverage among US children ages 9-12 years. In Survey 1, 60 participants (researchers, health care professionals, and other stakeholders engaged in HPV vaccination research) viewed 57 research topics about increasing HPV vaccination coverage and provided additional topics. We integrated their suggestions into the list and condensed similar items to reach a list of 38 topics. In Survey 2, 230 participants identified their top ten research priorities. The top HPV vaccination research priorities and their corresponding themes were misinformation (chosen by 50% of respondents, from the theme of vaccine confidence), starting at age 9 years (48%, primary care), and single dose (48%, other). The top ten research priorities also included vaccine communication (40%, primary care), system-wide approach (39%, health system and payers), community settings (39%, alternative settings), immunization registries (38%, policy), geography and rurality (37%, populations), school mandates (37%, policy), and near elimination of HPV cancers (37%, other). The proportion of participants selecting topics within each theme varied between 15% for health system and payers to 32% for alternative settings. These research priorities highlight research areas likely to yield impactful strategies for increasing HPV vaccination. Focusing US HPV vaccine research on these topics can optimize resource allocation, inform evidence-based interventions, and support policymaking to enhance vaccine uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.